SCHEMBL21070851

SCHEMBL21070851

CCC(N)CCOCC(F)CN(Cc1ccccc1)Cc1ccccc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 2/20 0.37
▸ KDM4E B2RXH2 1/20 0.34
▸ TSHR P16473 2/20 0.33
▸ CNR2 P34972 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ ATM Q13315 1/20 0.33
▸ ALDH1A1 P00352 2/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ CYP2D6 P10635 1/20 0.32
▸ MAPT P10636 1/20 0.32
▸ CYP2C9 P11712 1/20 0.32
▸ CYP2C19 P33261 1/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.32
▸ AOC3 Q16853 1/20 0.32
▸ BCHE P06276 1/20 0.32
▸ TACR1 P25103 1/20 0.32
▸ DPP7 Q9UHL4 1/20 0.30
▸ L3MBTL1 Q9Y468 1/20 0.30
▸ EPHX1 P07099 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25957832 0.84 POLB (0.45) POLBKDM4ETSHRCNR2MAPK1
SCHEMBL25957822 0.81 POLB (0.43) POLBKDM4ETSHRCNR2MAPK1
SCHEMBL25957745 0.81 POLB (0.43) POLBKDM4ETSHRCNR2MAPK1
SCHEMBL25957758 0.81 POLB (0.43) POLBKDM4ETSHRCNR2MAPK1
SCHEMBL21070978 0.81 CARM1 (0.37) POLBKDM4ETSHRCNR2MAPK1
SCHEMBL21070449 0.79 CARM1 (0.35) POLBKDM4EMAPK1ALDH1A1MAPT
SCHEMBL22609524 0.79 CARM1 (0.35) POLBKDM4EMAPK1ALDH1A1MAPT
SCHEMBL21070298 0.78 ALDH1A1 (0.40) POLBKDM4ETSHRMAPK1NPC1
SCHEMBL15688749 0.77 POLB (0.42) POLBKDM4ETSHRCNR2MAPK1
SCHEMBL21328902 0.77 POLB (0.42) POLBKDM4ETSHRCNR2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-12-14 — — US disclosed
US-11723980-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-08-15 — — US disclosed
US-20230106066-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-04-06 — — US disclosed
US-11318205-B1 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2022-05-03 — — US disclosed
US-10874743-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2020-12-29 — — US disclosed
US-20190192668-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2019-06-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10874743-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 POLB 2088/4885KDM4E 190/4885TSHR 3319/4885
US-20230106066-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 POLB 2088/4885KDM4E 190/4885TSHR 3319/4885
US-11723980-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 POLB 2088/4885KDM4E 190/4885TSHR 3319/4885
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 POLB 2088/4885KDM4E 190/4885TSHR 3319/4885
US-20190192668-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 POLB 2088/4885KDM4E 190/4885TSHR 3319/4885
US-11318205-B1 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 POLB 2088/4885KDM4E 190/4885TSHR 3319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback